Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers

Journal of Clinical Pathology
Muhtashim MianStefano Serra

Abstract

To investigate the predictive and prognostic values of DNA repair genes excision repair cross-complementation group 1 (ERCC1) and X-ray repair cross-complementing group 1 (XRCC1) in tumour samples from patients with a diagnosis of biliary tract cancer (BTC). Expressions of ERCC1 and XRCC1 were determined by immunohistochemistry (IHC) for 160 patients with BTC and association with clinicopathological features and patient survival was performed to evaluate their predictive and prognostic values. Neoplastic tissue showed much lower nuclear expression compared with non-neoplastic tissue for ERCC1 (median immunostaining score (IS)=0.7 (95% CI 0.2 to 1.3) vs 8.0 (95% CI 5.5 to 8.0), p<0.001) and XRCC1 (median IS=4.0 (95% CI 3.0 to 5.5) vs 8.0 (95% CI 8.0 to 12.0), p<0.001). High nuclear expression of both proteins was able to predict better overall survival (OS) in patients with gallbladder adenocarcinoma, distal bile duct and perihilar cholangiocarcinoma undergoing gemcitabine as adjuvant therapy (ERCC1: median OS estimate=39.7 vs 22.9 months, p=0.011; XRCC1: median OS estimate=33.8 vs 14.6 months, p=0.005). Intense cytoplasmic expression of XRCC1 was found in 12 patients; these patients had significantly more frequent lymph node me...Continue Reading

References

Oct 7, 1992·Journal of the National Cancer Institute·M DabholkarE Reed
Jan 1, 1989·Cytogenetics and Cell Genetics·H W MohrenweiserC A Weber
Jun 30, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E MiniT Mazzei
Feb 28, 2009·Gastroenterology·James E Everhart, Constance E Ruhl
Jun 15, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sufeng ChenHaiquan Chen
Mar 29, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shouyu WangJianwei Zhou
Oct 2, 2012·Human & Experimental Toxicology·B KarahalilD M Wilson
Oct 2, 2012·The Journal of Clinical Investigation·Sayaka Sekiya, Atsushi Suzuki
Dec 12, 2012·International Journal of Cancer. Journal International Du Cancer·Tarek Abdel-FatahSrinivasan Madhusudan
Apr 25, 2013·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Kyun Woo ParkMyung Ah Lee
Dec 12, 2013·Journal of Gastrointestinal Cancer·Vanessa da Costa MirandaRachel P Riechelmann
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Mar 22, 2014·Molecular and Clinical Oncology·Shigeru SakanoHideyasu Matsuyama
May 3, 2014·Journal of Gastroenterology and Hepatology·Jimme K WiggersThomas M van Gulik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis